Xeris Biopharma Shares Jump After Q3 Results Top Estimates

10:12 AM EST, 11/05/2026 (MT Newswires) -- Xeris Biopharma Holdings (XERS) shares surged 29% in Thursday trading after the company reported Q3 results that topped Wall Street estimates. In the three months ended Sept. 30, earnings were $0.06 per diluted share, compared with breakeven a year earlier. Three analysts polled by FactSet expected $0.02. Revenue rose to $107.2 million from $74.4 million a year earlier. Analysts projected $101.7 million. Xeris raised its 2026 revenue outlook to $395 million to $405 million from the previous range of $385 million to $390 million. Analysts expect $387.9 million. Price: 13.53, Change: +3.07, Percent Change: +29.30